nach oben

Cancer and Metastasis Reviews

Erschienen in:

13.01.2020

Neurological complications of pediatric cancer

verfasst von: Caren Armstrong, Lisa R. Sun

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Both the onset of various malignancies as well as the treatment of cancer can lead to neurologic symptoms which can be difficult to diagnose. In this review, we highlight the varied ways in which neurologic sequelae of cancer and its treatment manifest in children. Initial neurologic presentation may be secondary to mass effect or to immune-mediated paraneoplastic syndromes. Treatment effects on the nervous system may arise from surgery, chemotherapy, radiation, or bone marrow transplantation. In addition, the rapidly expanding field of immunotherapies for cancer has generated numerous new approaches to eradicating cancer including monoclonal antibodies, checkpoint inhibitors, and chimeric antigen receptor T cells (CAR-T cells), which have neurologic side effects mediated by immune responses that are also being recognized. Here we review common consult questions to the neurologist and our general approach to these scenarios including altered mental status, headaches, seizures, and sensorimotor complaints, considering the multifactorial nature of each.

Dobrovoljac, M., Hengartner, H., Boltshauser, E., & Grotzer, M. (2002). Delay in the diagnosis of paediatric brain tumours. Eur J Pediatr, 161(12), 663–667. https://doi.org/10.1007/s00431-002-1088-4.CrossRefPubMed

Reulecke, B. C., Erker, C. G., Fiedler, B. J., Niederstadt, T.-U., & Kurlemann, G. (2008). Brain tumors in children: Initial symptoms and their influence on the time span between symptom onset and diagnosis. J Child Neurol, 23(2), 178–183. https://doi.org/10.1177/0883073807308692.CrossRefPubMed

Ullrich, N. J. (2009). Neurologic sequelae of brain tumors in children. J Child Neurol, 24(11), 1446–1454. https://doi.org/10.1177/0883073809342491.CrossRefPubMed

Wells, E. M., & Packer, R. J. (2015). Pediatric brain tumors. CONTINUUM: Lifelong Learning in Neurology, 21(2), 373–396. https://doi.org/10.1212/01.CON.0000464176.96311.d1.CrossRefPubMed

Malbari, F., Gershon, T. R., Garvin, J. H., Allen, J. C., Khakoo, Y., Levy, A. S., & Dunkel, I. J. (2016). Psychiatric manifestations as initial presentation for pediatric CNS germ cell tumors, a case series. Childs Nerv Syst, 32(8), 1359–1362. https://doi.org/10.1007/s00381-016-3145-8.CrossRefPubMedPubMedCentral

Taylor M, Couto-Silva, A-C, Adan L, Trivin C, Sainte-Rose C, Zerah M, … Brauner R (2012). Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J Pediatr, 161(5), 855–63. doi:https://doi.org/10.1016/j.jpeds.2012.05.014.

Pretell-Mazzini, J., Chikwava, K. R., & Dormans, J. P. (2012). Low back pain in a child associated with acute onset cauda equina syndrome: a rare presentation of an aggressive vertebral hemangioma: a case report. J Pediatr Orthop, 32(3), 271–276. https://doi.org/10.1097/BPO.0b013e318247195a.CrossRefPubMed

Mora, J., & Wollner, N. (1999). Primary epidural non-Hodgkin lymphoma: spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma. Med Pediatr Oncol, 32(2), 102–105. https://doi.org/10.1002/(SICI)1096-911X(199902)32:2<102::AID-MPO6>3.0.CO;2-Y.CrossRefPubMed

Da Silva, A. N., Lopes, M. B., & Schiff, D. (2006). Rare pathological variants and presentations of primary central nervous system lymphomas. Neurosurg Focus, 21(5), E1–E7. https://doi.org/10.3171/foc.2006.21.5.8.CrossRef

10.

Wilson, R. E., Oleszek, J. L., & Clayton, G. H. (2007). Pediatric spinal cord tumors and masses. J Spinal Cord Med, 30(sup1), S15–S20. https://doi.org/10.1080/10790268.2007.11753963.CrossRefPubMedPubMedCentral

11.

Ma, G. M., Chow, J. S., & Taylor, G. A. (2019). Review of paraneoplastic syndromes in children. Pediatr Radiol, 49(4), 534–550. https://doi.org/10.1007/s00247-019-04371-y.CrossRefPubMed

12.

Nikolic, D. M., Nikolic, A. V., Lavrnic, D. V., Medjo, B. P., & Ivanovski, P. I. (2012). Childhood-onset myasthenia gravis with thymoma. Pediatr Neurol, 46(5), 329–331. https://doi.org/10.1016/j.pediatrneurol.2012.02.025.CrossRefPubMed

13.

Wells, E. M., & Dalmau, J. (2011). Paraneoplastic neurologic disorders in children. Curr Neurol Neuroscie Rep, 11(2), 187–194. https://doi.org/10.1007/s11910-010-0169-4.CrossRef

14.

Dalmau, J., & Rosenfeld, M. R. (2008). Paraneoplastic syndromes of the CNS. Lancet Neurol, 7(4), 327–340. https://doi.org/10.1016/S1474-4422(08)70060-7.CrossRefPubMedPubMedCentral

15.

Graus, F., Delattre, J. Y., Antoine, J. C., Dalmau, J., Giometto, B., Grisold, W., Honnorat, J., Smitt, P. S., Vedeler Ch, Verschuuren, J. J., Vincent, A., & Voltz, R. (2004). Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry, 75(8), 1135–1140. https://doi.org/10.1136/jnnp.2003.034447.CrossRefPubMedPubMedCentral

16.

Pranzatelli, M. R., Tate, E. D., Swan, J. A., Travelstead, A. L., Colliver, J. A., Verhulst, S. J., Crosley, C. J., Graf, W. D., Joseph, S. A., Kelfer, H. M., & Raju, G. P. (2010). B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord, 25(2), 238–242. https://doi.org/10.1002/mds.22941.CrossRefPubMed

17.

Shams’ili, S., de Beukelaar, J., Gratama, J. W., Hooijkaas, H., van den Bent, M., van’t Veer, M., & Sillevis Smitt, P. (2006). An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol, 253(1), 16–20. https://doi.org/10.1007/s00415-005-0882-0.CrossRefPubMed

18.

Honnorat, J., Didelot, A., Karantoni, E., Ville, D., Ducray, F., Lambert, L., Deiva, K., Garcia, M., Pichit, P., Cavillon, G., Rogemond, V., DeLattre, J., & Tardieu, M. (2013). Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 80(24), 2226–2232. https://doi.org/10.1212/WNL.0b013e318296e9c3.CrossRefPubMed

19.

Florance-Ryan, N., & Dalmau, J. (2010). Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr, 22(6), 739–744. https://doi.org/10.1097/MOP.0b013e3283402d2f.CrossRefPubMed

20.

Lebas, A., Husson, B., Didelot, A., Honnorat, J., & Tardieu, M. (2010). Expanding spectrum of encephalitis with NMDA receptor antibodies in young children. J Child Neurol, 25(6), 742–745. https://doi.org/10.1177/0883073809343319.CrossRefPubMed

21.

Haberlandt, E., Bast, T., Ebner, A., Holthausen, H., Kluger, G., Kravljanac, R., Kröll-Seger, J., Kurlemann, G., Makowski, C., Rostasy, K., Tuschen-Hofstätter, E., Weber, G., Vincent, A., & Bien, C. G. (2011). Limbic encephalitis in children and adolescents. Arch Dis Child, 96(2), 186–191. https://doi.org/10.1136/adc.2010.183897.CrossRefPubMed

22.

Nosadini M, Toldo I, Tascini B, Bien CG, Parmeggiani L, De Gaspari P, … Sartori S (2019). LGI1 and CASPR2 autoimmunity in children: systematic literature review and report of a young girl with Morvan syndrome. J Neuroimmunol, 335, 577008. doi:https://doi.org/10.1016/J.JNEUROIM.2019.577008.

23.

Nikolaus, M., Jackowski-Dohrmann, S., Prüss, H., Schuelke, M., & Knierim, E. (2018). Morvan syndrome associated with CASPR2 and LGI1 antibodies in a child. Neurology, 90(4), 183–185. https://doi.org/10.1212/WNL.0000000000004861.CrossRefPubMed

24.

Allen, N. M., McKeon, A., O’Rourke, D. J., O’Meara, A., & King, M. D. (2012). Excessive blinking and ataxia in a child with occult neuroblastoma and voltage-gated potassium channel antibodies. Pediatrics, 129(5), e1348–e1352. https://doi.org/10.1542/peds.2011-2690.CrossRefPubMed

25.

Rosenfeld, M. R. (2018). Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia. Up To Date, 12, 1–12.

26.

Sharp, L., & Vernino, S. (2012). Paraneoplastic neuromuscular disorders. Muscle Nerve, 46(6), 839–840. https://doi.org/10.1002/mus.23502.CrossRef

27.

Amini, A., Lang, B., Heaney, D., & Irani, S. R. (2016). Multiple sequential antibody-associated syndromes with a recurrent mutated neuroblastoma. Neurology, 87(6), 634–636. https://doi.org/10.1212/WNL.0000000000002945.CrossRefPubMedPubMedCentral

28.

Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, … Honnorat J (2004). FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain, 127(10), 2331–2338. doi:https://doi.org/10.1093/brain/awh247.

29.

Linke, R., Schroeder, M., Helmberger, T., & Voltz, R. (2004). Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis. Neurology, 63(2), 282–286. https://doi.org/10.1212/01.WNL.0000129983.06983.4E.CrossRefPubMed

30.

Blaes, F., Pike, M. G., & Lang, B. (2008). Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Neuroimmunol, 201, 221–226. https://doi.org/10.1016/j.jneuroim.2008.05.033.CrossRefPubMed

31.

van Vuurden, D. G., Plötz, F. B., de Jong, M., Bokenkamp, A., & van Wijk, J. A. E. (2005). Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome. Pediatr Nephrol, 20(11), 1655–1656. https://doi.org/10.1007/s00467-005-2004-8.CrossRefPubMed

32.

Sillevis Smitt, P., Grefkens, J., De Leeuw, B., Van Den Bent, M., Van Putten, W., Hooijkaas, H., & Vecht, C. (2002). Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol, 249(6), 745–753. https://doi.org/10.1007/s00415-002-0706-4.CrossRefPubMed

33.

Chong, C., Soon, D. T. L., & Yeo, L. L. L. (2019). Opsoclonus - myoclonus syndrome. J Clin Neurosci, 61, 254–255. https://doi.org/10.1016/j.jocn.2018.10.099.CrossRef

34.

Tate, E. D., Allison, T. J., Pranzatelli, M. R., & Verhulst, S. J. (2005). Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs, 22(1), 8–19. https://doi.org/10.1177/1043454204272560.CrossRefPubMed

35.

Morales La Madrid, A., Rubin, C. M., Kohrman, M., Pytel, P., & Cohn, S. L. (2012). Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma. Pediatr Blood Cancer, 58(3), 472–474. https://doi.org/10.1002/pbc.23131.CrossRefPubMed

36.

Fisher, P. G., Wechsler, D. S., & Singer, H. S. (1994). Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol, 10(4), 309–312. https://doi.org/10.1016/0887-8994(94)90127-9.CrossRefPubMed

37.

Wilfong, A. A., Parke, J. T., & McCrary, J. A. (1992). Opsoclonus-myoclonus with Beckwith-Wiedemann syndrome and hepatoblastoma. Pediatr Neurol, 8(1), 77–79. https://doi.org/10.1016/0887-8994(92)90060-c.CrossRefPubMed

38.

Swart, J. F., De Kraker, J., & Van der Lely, N. (2002). Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome. Eur J Pediatr, 161(5), 255–258. https://doi.org/10.1007/s00431-002-0934-8.CrossRefPubMed

39.

McGarvey, C. K., Applegate, K., Lee, N. D., & Sokol, D. K. (2006). False-positive metaiodobenzylguanidine scan for neuroblastoma in a child with opsoclonus-myoclonus syndrome treated with adrenocorticotropic hormone (ACTH). J Child Neurol, 21(7), 606–610. https://doi.org/10.1177/08830738060210070801.CrossRefPubMed

40.

Brunklaus, A., Pohl, K., Zuberi, S. M., & De Sousa, C. (2012). Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. https://doi.org/10.1136/adc.2010.204792.

41.

Baizabal-Carvallo, J. F., Stocco, A., Muscal, E., & Jankovic, J. (2013). The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord, 28(4), 543–547. https://doi.org/10.1002/mds.25354.CrossRefPubMed

42.

Mohammad, S. S., Fung, V. S. C., Grattan-Smith, P., Gill, D., Pillai, S., Ramanathan, S., et al. (2014). Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord, 29(12), 1539–1542. https://doi.org/10.1002/mds.25999.CrossRefPubMed

43.

Yeshokumar, A. K., Sun, L. R., Klein, J. L., Baranano, K. W., & Pardo, C. A. (2016). Gait disturbance as the presenting symptom in young children with anti-NMDA receptor encephalitis. Pediatrics, 138(3), e20160901. https://doi.org/10.1542/peds.2016-0901.CrossRefPubMed

44.

Darnell, R. B. (2007). NMDA receptor as a target in paraneoplastic encephalitis. Ann Neurol, 61(1), 3–4. https://doi.org/10.1002/ana.21074.CrossRefPubMed

45.

Dalmau, J., Tüzün, E., Wu, H., & Masjuan, J. (2007). Paraneoplastic anti–N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol, 61(1), 25–36.CrossRefPubMedPubMedCentral

46.

Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008). Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol, 7(12), 1091–1098. https://doi.org/10.1016/S1474-4422(08)70224-2.CrossRefPubMedPubMedCentral

47.

Kunstreich, M., Kreth, J. H., Oommen, P. T., Schaper, J., Karenfort, M., Aktas, O., Tibussek, D., Distelmaier, F., Borkhardt, A., & Kuhlen, M. (2017). Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma. Eur J Paediatr Neurol, 21(4), 661–665. https://doi.org/10.1016/j.ejpn.2017.03.005.CrossRefPubMed

48.

Chan, D. W. S., Thomas, T., Lim, M., Ling, S., Woodhall, M., & Vincent, A. (2017). Focal status epilepticus and progressive dyskinesia: a novel phenotype for glycine receptor antibody-mediated neurological disease in children. Eur J Paediatr Neurol, 21(2), 414–417. https://doi.org/10.1016/j.ejpn.2016.08.013.CrossRefPubMed

49.

Spatola, M., Sabater, L., Planagumà, J., Martínez-Hernandez, E., Armangué, T., Prüss, H., Iizuka, T., Caparó Oblitas, R. L., Antoine, J. C., Li, R., Heaney, N., Tubridy, N., Munteis Olivas, E., Rosenfeld, M. R., Graus, F., & Dalmau, J. (2018). Encephalitis with mGluR5 antibodies: symptoms and antibody effects. Neurology, 90(22), e1964–e1972. https://doi.org/10.1212/WNL.0000000000005614.CrossRefPubMedPubMedCentral

50.

Rudock R, Helis J, & Mar SS (2017). Anti-glutamic acid decarboxylase limbic encephalitis. In Pediatric demyelinating diseases of the central nervous system and their mimics (pp. 67–73). Springer International Publishing. doi:https://doi.org/10.1007/978-3-319-61407-6_9.

51.

Gresa-Arribas, N., Titulaer, M. J., Torrents, A., Aguilar, E., McCracken, L., Leypoldt, F., Gleichman, A. J., Balice-Gordon, R., Rosenfeld, M. R., Lynch, D., Graus, F., & Dalmau, J. (2014). Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol, 13(2), 167–177. https://doi.org/10.1016/S1474-4422(13)70282-5.CrossRefPubMed

52.

Rosenfeld, M. R., & Dalmau, J. (2011). Anti-NMDA-receptor encephalitis and other synaptic autoimmune disorders. Curr Treat Options Neurol, 13(3), 324–332. https://doi.org/10.1007/s11940-011-0116-y.CrossRefPubMedPubMedCentral

53.

Gungor, S., Kilic, B., Arslan, M., Ozgen, U., & Dalmau, J. (2017). Hodgkin’s lymphoma associated with paraneoplastic cerebellar degeneration in children: a case report and review of the literature. Childs Nerv Syst, 33(3), 509–512. https://doi.org/10.1007/s00381-016-3284-y.CrossRefPubMed

54.

Nakamura, T., Morimoto, N., Goto, F., Shioda, Y., Hoshino, H., Kubota, M., & Taiji, H. (2012). Langerhans cell histiocytosis with disequilibrium. Auris Nasus Larynx, 39(6), 627–630. https://doi.org/10.1016/j.anl.2012.01.003.CrossRefPubMed

55.

Emir, S., Tezer Kutluk, M., Göğüş, S., & Büyükpamukçu, M. (2000). Paraneoplastic cerebellar degeneration and horner syndrome: association of two uncommon findings in a child with hodgkin disease. Am J Pediatr Hematol/Oncol, 22(2), 158–161. https://doi.org/10.1097/00043426-200003000-00015.CrossRef

56.

Greenlee, J. E. (2013). Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol, 15(2), 185–200. https://doi.org/10.1007/s11940-012-0215-4.CrossRefPubMedPubMedCentral

57.

Ojeda, V. J., & Ojeda, V. J. (1984). Necrotizing myelopathy associated with malignancy. a clinicopathologic study of two cases and literature review. Cancer, 53(5), 1115–1123. https://doi.org/10.1002/1097-0142(19840301)53:5<1115::aid-cncr2820530517>3.0.co;2-w.CrossRefPubMed

58.

Pittock, S. J., & Lennon, V. A. (2008). Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol, 65(5), 629–632. https://doi.org/10.1001/archneur.65.5.629.CrossRefPubMed

59.

de Buys Roessingh, A. S., Loriot, M. H., Wiesenauer, C., & Lallier, M. (2009). Lambert-Eaton myasthenic syndrome revealing an abdominal neuroblastoma. J Pediatr Surg, 44(8), E5–E7. https://doi.org/10.1016/j.jpedsurg.2009.04.023.CrossRefPubMed

60.

Sun, L. R., & Cooper, S. (2018). Neurological complications of the treatment of pediatric neoplastic disorders. Pediatr Neurol, 85, 33–42. https://doi.org/10.1016/j.pediatrneurol.2018.05.011.CrossRefPubMed

61.

Küper, M., & Timmann, D. (2013). Cerebellar mutism. Brain Lang, 127(3), 327–333. https://doi.org/10.1016/J.BANDL.2013.01.001.CrossRefPubMed

62.

Neil, E. C., Hanmantgad, S., & Khakoo, Y. (2016). Neurological complications of pediatric cancer. J Child Neurol, 31(12), 1412–1420. https://doi.org/10.1177/0883073815620673.CrossRefPubMed

63.

Newton HB (2012). Neurological complications of chemotherapy to the central nervous system. In Handbook of clinical neurology (Vol. 105, pp. 903–916). Elsevier B.V. doi:https://doi.org/10.1016/B978-0-444-53502-3.00031-8.

64.

Staff, N. P, Grisold, A., Grisold, W., & Windebank, A. J. (2017). Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol, 81(6), 772–781. https://doi.org/10.1002/ana.24951.CrossRef

65.

Schiff, D., Wen, P. Y., & van den Bent, M. J. (2009). Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol, 6(10), 596–603. https://doi.org/10.1038/nrclinonc.2009.128.CrossRefPubMed

66.

Wick, W., Hertenstein, A., & Platten, M. (2016). Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol, 17(12), e529–e541. https://doi.org/10.1016/S1470-2045(16)30571-X.CrossRefPubMed

67.

Cordelli, D. M., Masetti, R., Zama, D., Toni, F., Castelli, I., Ricci, E., Franzoni, E., & Pession, A. (2017). Central nervous system complications in children receiving chemotherapy or hematopoietic stem cell transplantation. Front Pediatr, 5, 105. https://doi.org/10.3389/fped.2017.00105.CrossRefPubMedPubMedCentral

68.

Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, Von Geldern G, Moskowitz CH, … Bennett CL (2014). Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer, 120(16), 2464–2471. doi:https://doi.org/10.1002/cncr.28712.

69.

Toxicology and Environmental Health Information Program (TEHIP). (2019). TOXNET. National Library of Medicine. Retrieved November 26, 2019, from https://toxnet.nlm.nih.gov/index.html Accessed 12/2/2019.

70.

Aspesberro, F., Milewski, L. S., & Brogan, T. V. (2014). Acute central nervous system complications in pediatric hematopoietic stem cell patients. J Pediatr Intensive Care, 3, 169–181. https://doi.org/10.3233/PIC-14100.CrossRefPubMed

71.

Tibussek D, Natesirinilkul R, Sun LR, Wasserman, B. A., Brandao LR, deVeber G, … deVeber G (2016). Severe cerebral vasospasm and childhood arterial ischemic stroke after intrathecal cytarabine. Pediatrics, 137(2), e20152143–e20152143. doi:https://doi.org/10.1542/peds.2015-2143.

72.

Sait, S., & Modak, S. (2017). Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther, 17(10), 889–904. https://doi.org/10.1080/14737140.2017.1364995.CrossRefPubMedPubMedCentral

73.

Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Pröschel, M., & Noble, M. (2008). Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol, 7(4), 12. https://doi.org/10.1186/jbiol69.CrossRefPubMedPubMedCentral

74.

Ewins, K., Malone, A., Phelan, E., Webb, D., McHugh, J. C., & Smith, O. (2017). Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history? Br J Haematol, 179(2), 294–297. https://doi.org/10.1111/bjh.14921.CrossRefPubMed

75.

Judge, C., Moheb, N., & Melinosky, C. (2019). Nilotinib-associated demyelinating disease. Neurology, 92(Suppl 15), P2.2–P093.

76.

Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, … Widemann BC (2016). Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Eng J Med, 375(26), 2550–2560. doi:https://doi.org/10.1056/NEJMoa1605943.

77.

Grace, R. F., Dahlberg, S. E., Neuberg, D., Sallan, S. E., Connors, J. M., Neufeld, E. J., Deangelo, D. J., & Silverman, L. B. (2011). The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol, 152(4), 452–459. https://doi.org/10.1111/j.1365-2141.2010.08524.x.CrossRefPubMedPubMedCentral

78.

Mitchell LG, Andrew M, Abshire T, Halton J, Anderson R, Cherrick I, … Way C (2003). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase: results of the Prophylactic antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) study. Cancer, 97(2), 508–516. doi:https://doi.org/10.1002/cncr.11042.

79.

Caruso, V., Iacoviello, L., Di Castelnuovo, A., Storti, S., Mariani, G., De Gaetano, G., & Donati, M. B. (2006). Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. https://doi.org/10.1182/blood-2006-04-015511.

80.

Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, … Möricke A (2019). THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica, 104(4), 756–765. doi:https://doi.org/10.3324/haematol.2018.194175.

81.

Malhotra, P., Jain, S., & Kapoor, G. (2018). Symptomatic cerebral sinovenous thrombosis associated with l-asparaginase in children with acute lymphoblastic leukemia: a single institution experience over 17 years. J Pediatr Hematol Oncol, 40(7), e450–e453. https://doi.org/10.1097/MPH.0000000000001127.CrossRefPubMed

82.

Nicolao, P., & Giometto, B. (2003). Neurological toxicity of ifosfamide. Oncology, 65(Suppl 2), 11–16. https://doi.org/10.1159/000073352.CrossRefPubMed

83.

Taupin, D., Racela, R., & Friedman, D. (2014). Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. Clin EEG Neurosci, 45(3), 222–225. https://doi.org/10.1177/1550059413500777.CrossRefPubMed

84.

Bhojwani, D., Sabin, N. D., Pei, D., Yang, J. J., Khan, R. B., Panetta, J. C., Krull, K. R., Inaba, H., Rubnitz, J. E., Metzger, M. L., Howard, S. C., Ribeiro, R. C., Cheng, C., Reddick, W. E., Jeha, S., Sandlund, J. T., Evans, W. E., Pui, C. H., & Relling, M. V. (2014). Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol, 32(9), 949–959. https://doi.org/10.1200/JCO.2013.53.0808.CrossRefPubMedPubMedCentral

85.

Inaba, H., Khan, R. B., Laningham, F. H., Crews, K. R., Pui, C. H., & Daw, N. C. (2008). Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol, 19(1), 178–184. https://doi.org/10.1093/annonc/mdm466.CrossRefPubMed

86.

Cheung, Y. T., Sabin, N. D., Reddick, W. E., Bhojwani, D., Liu, W., Brinkman, T. M., Glass, J. O., Hwang, S. N., Srivastava, D., Pui, C. H., Robison, L. L., Hudson, M. M., & Krull, K. R. (2016). Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Haematol, 3(10), 456–466. https://doi.org/10.1016/S2352-3026(16)30110-7.CrossRef

87.

Koh, S., Nelson, M. D., Kovanlikaya, A., & Chen, L. S. (1999). Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol, 21(2), 576–578. https://doi.org/10.1016/S0887-8994(99)00040-5.CrossRefPubMed

88.

Junna, M. R., & Rabinstein, A. A. (2007). Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. J Neurol Neurosurg Psychiatry, 78(12), 1410–1411. https://doi.org/10.1136/jnnp.2007.121806.CrossRefPubMedPubMedCentral

89.

Antoine, J. C., & Camdessanché, J. P. (2007). Peripheral nervous system involvement in patients with cancer. Lancet Neurol, 6(1), 75–86. https://doi.org/10.1016/S1474-4422(06)70679-2.CrossRefPubMed

90.

Tang, J.-H., Tian, J.-M., Sheng, M., Hu, S.-Y., Li, Y., Zhang, L.-Y., Gu, Q., & Wang, Q. (2016). Study of posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia after induction chemotherapy. J Child Neurol, 31(3), 279–284. https://doi.org/10.1177/0883073815589758.CrossRefPubMed

91.

Landi, D. B., Thompson, E. M., & Ashley, D. M. (2018). Immunotherapy for pediatric brain tumors. Neuroimmunol Neuroinflamm, 5, 29. https://doi.org/10.20517/2347-8659.2018.35.CrossRef

92.

Kabir, T. F., Chauhan, A., Anthony, L., & Hildebrandt, G. C. (2018). Immune checkpoint inhibitors in pediatric solid tumors: status in 2018. Ochsner J, 18(4), 370–376. https://doi.org/10.31486/toj.18.0055.CrossRefPubMedPubMedCentral

93.

AlHarbi M, Mobark NA, AlMubarak L, Aljelaify R, AlSaeed M, Almutairi A, … Abedalthagafi M (2018). Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency Saudi human genome project View project medulloblastoma View project, 23(12), 1401–1406. doi:https://doi.org/10.1634/theoncologist.2018-0163.

94.

Gorsi H, Malicki DM, Barsan, V, Tumblin M, Yeh-Nayre L, Milburn M, … Crawford JR (2019). Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: a single institutional experience. J Pediatr Hematol/Oncol, 41(4), e235–241. doi:https://doi.org/10.1097/MPH.0000000000001339.

95.

Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019). Towards immunotherapy for pediatric brain tumors. Trends Immunol, 40(8), 748–761. https://doi.org/10.1016/j.it.2019.05.009.CrossRefPubMed

96.

Williams TJ, Benavides DR, Patrice, K A, Dalmau JO, De Ávila AL R, Le DT, … Mowry EM (2016). Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol, 73(8), 928–933. doi:https://doi.org/10.1001/jamaneurol.2016.1399.

97.

Zekeridou, A., & Lennon, V. A. (2019). Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc, 94(9), 1865–1878. https://doi.org/10.1016/j.mayocp.2019.02.003.CrossRefPubMed

98.

Dalakas, M. C. (2018). Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord, 11, 1756286418799864. https://doi.org/10.1177/1756286418799864.CrossRefPubMedPubMedCentral

99.

Brudno, J. N., & Kochenderfer, J. N. (2019). Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev, 34, 45–55. https://doi.org/10.1016/j.blre.2018.11.002.CrossRefPubMed

100.

Gust, J., Hay KA, Hanafi L A, Li D, Myerson D, Gonzalez-Cuyar LF, … Turtle CJ (2017). Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov doi:https://doi.org/10.1158/2159-8290.CD-17-0698.

101.

Hay, K. A. (2018). Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. https://doi.org/10.1111/bjh.15644.

102.

Santomasso BD, Park JH, Salloum D, Riviere, I., Flynn J, Mead E, … Brentjens RJ (2018). Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. doi:https://doi.org/10.1158/2159-8290.CD-17-1319.

103.

Willis, M. D., & Robertson, N. P. (2019). Neurotoxicity of novel cancer immunotherapies. J Neurol, 266, 2087–2089. https://doi.org/10.1007/s00415-019-09444-4.CrossRefPubMedPubMedCentral

104.

Gust, J., Taraseviciute, A., & Turtle, C. J. (2018). Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs, 32(12), 1091–1101. https://doi.org/10.1007/s40263-018-0582-9.CrossRefPubMedPubMedCentral

105.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, … Pazdur R (2018). FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist, 23(8), 943–947. doi:https://doi.org/10.1634/theoncologist.2018-0028.

106.

Reynolds, M. R., Haydon, D. H., Caird, J., & Leonard, J. R. (2016). Radiation-induced moyamoya syndrome after proton beam therapy in the pediatric patient: a case series. Pediatr Neurosurg, 51(6), 297–301. https://doi.org/10.1159/000446075.CrossRefPubMed

107.

Meadows, A. T., Massari, D. J., Fergusson, J., Gordon, J., Littman, P., & Moss, K. (1981). Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet, 2(8254), 1015–1018. https://doi.org/10.1016/S0140-6736(81)91216-2.CrossRefPubMed

108.

Amirjamshidi, A., & Abbassioun, K. (2000). Radiation-induced tumors of the central nervous system occurring in childhood and adolescence. Childs Nerv Syst, 16(7), 390–397. https://doi.org/10.1007/s003819900125.CrossRefPubMed

109.

Gastelum, E., Sear, K., Hills, N., Roddy, E., Randazzo, D., Chettout, N., Hess, C., Cotter, J., Haas-Kogan, D. A., Fullerton, H., & Mueller, S. (2015). Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. J Child Neurol, 30(7), 842–849. https://doi.org/10.1177/0883073814544364.CrossRefPubMed

110.

Strenger, V., Sovinz, P., Lackner, H., Dornbusch, H. J., Lingitz, H., Eder, H. G., Moser, A., & Urban, C. (2008). Intracerebral cavernous hemangioma after cranial irradiation in childhood: incidence and risk factors. Strahlenther Onkol, 184(5), 276–280. https://doi.org/10.1007/s00066-008-1817-3.CrossRefPubMed

111.

Lew, S. M., Morgan, J. N., Psaty, E., Lefton, D. R., Allen, J. C., & Abbott, R. (2006). Cumulative incidence of radiation-induced cavernomas in long-term survivors of medulloblastoma. J Neurosurg, 104(Suppl 2), 103–107. https://doi.org/10.3171/ped.2006.104.2.6.CrossRefPubMed

112.

Sciubba, D. M., Gallia, G. L., Recinos, P., Garonzik, I. M., & Clatterbuck, R. E. (2006). Intracranial aneurysm following radiation therapy during childhood for a brain tumor: case report and review of the literature. J Neurosurg, 105(2), 134–139. https://doi.org/10.3171/ped.2006.105.2.134.CrossRefPubMed

113.

Fan, E. P., Heiber, G., Gerard, E. E., & Schuele, S. (2018). Stroke-like migraine attacks after radiation therapy: a misnomer? Epilepsia, 59(1), 259–268. https://doi.org/10.1111/epi.13963.CrossRefPubMed

114.

Wai, K., Balabanski, A., Chia, N., & Kleinig, T. (2017). Reversible hemispheric hypoperfusion in two cases of SMART syndrome. J Clin Neurosci, 43, 146–148. https://doi.org/10.1016/j.jocn.2017.05.013.CrossRefPubMed

115.

Stubblefield, M. D. (2017). Neuromuscular complications of radiation therapy. Muscle Nerve, 56(6), 1031–1040. https://doi.org/10.1002/mus.25778.CrossRefPubMed

116.

Neglia, J. P., Robison, L. L., Stovall, M., Liu, Y., Packer, R. J., Hammond, S., Yasui, Y., Kasper, C. E., Mertens, A. C., Donaldson, S. S., Meadows, A. T., & Inskip, P. D. (2006). New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst, 98(21), 1528–1537. https://doi.org/10.1093/jnci/djj411.CrossRefPubMed

117.

Schmidt-Hieber, M., Silling, G., Schalk, E., Heinz, W., Panse, J., Penack, O., Christopeit, M., Buchheidt, D., Meyding-Lamadé, U., Hähnel, S., Wolf, H. H., Ruhnke, M., Schwartz, S., & Maschmeyer, G. (2016). CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-guidelines of the infectious DiseasesWorking party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol, 27(7), 1207–1225. https://doi.org/10.1093/annonc/mdw155.CrossRefPubMedPubMedCentral

118.

Schoettler, M., Duncan, C., & Lehmann, L. (2019). Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab. Pediatr Transplant, 23(3), e13381. https://doi.org/10.1111/petr.13381.CrossRefPubMedPubMedCentral

119.

Callahan, M. J., MacDougall, R. D., Bixby, S. D., Voss, S. D., Robertson, R. L., & Cravero, J. P. (2018). Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations. Pediatr Radiol, 48(1), 21–30. https://doi.org/10.1007/s00247-017-4023-6.CrossRefPubMed

120.

Tekes, A., Senglaub, S. S., Ahn, E. S., Huisman, T. A. G. M., & Jackson, E. M. (2018). Ultrafast brain MRI can be used for indications beyond shunted hydrocephalus in pediatric patients. Am J Neuroradiol, 39(8), 1515–1518. https://doi.org/10.3174/ajnr.A5724.CrossRefPubMedPubMedCentral

121.

Tuma, R., & DeAngelis, L. M. (2000). Altered mental status in patients with cancer. Arch Neurol, 57(12), 1727–1731. https://doi.org/10.1001/archneur.57.12.1727.CrossRefPubMed

122.

Khan, R. B., Hunt, D. L., Boop, F. A., Sanford, R. A., Merchant, T. E., Gajjar, A., & Kun, L. E. (2005). Seizures in children with primary brain tumors: Incidence and long-term outcome. Epilepsy Res, 64(3), 85–91. https://doi.org/10.1016/j.eplepsyres.2005.03.007.CrossRefPubMed

123.

Ibrahim, K., & Appleton, R. E. (2004). Seizures as the presenting symptom of brain tumours in children. Seizure, 13(2), 108–112. https://doi.org/10.1016/S1059-1311(03)00083-9.CrossRefPubMed

124.

Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, … Cairncross JG (2000). Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the quality standards Subcommittee of the American Academy of neurology. Neurology, 54(10), 1886–1893. doi:https://doi.org/10.1212/WNL.54.10.1886.

125.

Hardesty, D. A., Sanborn, M. R., Parker, W. E., & Storm, P. B. (2011). Perioperative seizure incidence and risk factors in 223 pediatric brain tumor patients without prior seizures: clinical article. J Neurosurg Pediatr. https://doi.org/10.3171/2011.3.PEDS1120.

126.

Patsalos, P. N., & St. Louis, E. K. (2018). The epilepsy prescriber’s guide to antiepileptic drugs (3rd ed.). Cambridge: Cambridge University Press. https://doi.org/10.1017/9781108669399.CrossRef

127.

The Childhood Brain Tumor Consortium. (1991). The epidemiology of headache among children with brain tumor. Headache in children with brain tumors. J Neuro-Oncol, 10(1), 31–46. https://doi.org/10.1007/bf00151245.CrossRef

128.

Kirby, S., & Purdy, R. A. (2007). Headache and brain tumors. Curr Neurol Neurosci Rep, 7(2), 110–116. https://doi.org/10.1007/s11910-007-0005-7.CrossRefPubMed

129.

Demaree, C. J., Soliz, J. M., & Gebhardt, R. (2016). Cancer seeding risk from an epidural blood patch in patients with leukemia or lymphoma. Pain Med, 18(4), 218. https://doi.org/10.1093/pm/pnw218.CrossRef

130.

Rusch, R., Schulta, C., Hughes, L., & Withycombe, J. S. (2014). Evidence-based practice recommendations to prevent/manage post-lumbar puncture headaches in pediatric patients receiving intrathecal chemotherapy. J Pediatr Oncol Nurs, 31(4), 230–238. https://doi.org/10.1177/1043454214532026.CrossRefPubMed

131.

Lee, L. C.-Y., Sennett, M., & Erickson, J. M. (2007). Prevention and management of post–lumbar puncture headache in pediatric oncology patients. J Pediatr Oncol Nurs, 24(4), 200–207. https://doi.org/10.1177/1043454207303884.CrossRefPubMed

132.

Kranick, S. M., Campen, C. J., Kasner, S. E., Kessler, S. K., Zimmerman, R. A., Lustig, R. A., Phillips, P. C., Beslow, L. A., Ichord, R., & Fisher, M. J. (2013). Headache as a risk factor for neurovascular events in pediatric brain tumor patients. Neurology, 80(16), 1452–1456. https://doi.org/10.1212/WNL.0b013e31828cf81e.CrossRefPubMedPubMedCentral

133.

Black, D., Bartleson, J., Bell, M., & Lachance, D. (2006). SMART: stroke-like migraine attacks after radiation therapy. Cephalalgia, 26(9), 1137–1142. https://doi.org/10.1111/j.1468-2982.2006.01184.x.CrossRefPubMed

134.

Sporns PB, Sträter R, Minnerup, J, Wiendl H, Hanning U, Chapot R, … Kemmling A (2019). Feasibility, safety, and outcome of endovascular recanalization in childhood stroke: the Save ChildS Study. JAMA Neurol. doi:https://doi.org/10.1001/jamaneurol.2019.3403.

135.

Bigi, S., Dulcey, A., Gralla, J., Bernasconi, C., Melliger, A., Datta, A. N., Arnold, M., Kaesmacher, J., Fluss, J., Hackenberg, A., Maier, O., Weber, J., Poloni, C., Fischer, U., & Steinlin, M. (2018). Feasibility, safety, and outcome of recanalization treatment in childhood stroke. Ann Neurol, 83(6), 1125–1132. https://doi.org/10.1002/ana.25242.CrossRefPubMed

136.

Amlie-Lefond, C., & Wainwright, M. S. (2019). Organizing for acute arterial ischemic stroke in children. Stroke, 50(12), 3662–3668. https://doi.org/10.1161/STROKEAHA.119.025497.CrossRefPubMed

137.

Furuhata, M., Aihara, Y., Eguchi, S., Horiba, A., Tanaka, M., Komori, T., & Okada, Y. (2014). Pediatric medulloblastoma presenting as cerebellar hemorrhage: a case report. No shinkei geka. Neurol Surg, 42(6), 545–551.

138.

Wilson, M. P., Johnson, E. S., Hawkins, C., Atkins, K., Alshaya, W., & Pugh, J. A. (2016). Hemorrhagic presentations of cerebellar pilocytic astrocytomas in children resulting in death: report of 2 cases. J Neurosurg Pediatr, 17(4), 446–452. https://doi.org/10.3171/2015.10.PEDS1580.CrossRefPubMed

139.

Packer, R. J., Rorke, L. B., Lange, B. J., Siegel, K. R., & Evans, A. E. (1985). Cerebrovascular accidents in children with cancer. Pediatrics, 76(2), 194–201.PubMed

140.

Bajzar, L., Chan, A. K., Massicotte, M. P., & Mitchell, L. G. (2006). Thrombosis in children with malignancy. Curr Opin Pediatr, 18(1), 1–9. https://doi.org/10.1097/01.mop.0000193270.09001.ea.CrossRefPubMed

141.

Herrlinger, U., Schabet, M., Bitzer, M., Petersen, D., & Krauseneck, P. (1999). Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neuro-Oncol, 43(3), 219–226. https://doi.org/10.1023/A:1006298201101.CrossRef

142.

Bühring, U., Herrlinger, U., Krings, T., Thiex, R., Weller, M., & Küker, W. (2001). MRI features of primary central nervous system lymphomas at presentation. Neurology, 57(3), 393–396. https://doi.org/10.1212/wnl.57.3.393.CrossRefPubMed

143.

Bjornard, K. L., Leventaki, V., Nichols, K. E., Sandlund, J. T., Prockop, S., & Ehrhardt, M. J. (2018). Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. Pediatr Blood Cancer, 65(12), e27415. https://doi.org/10.1002/pbc.27415.CrossRefPubMedPubMedCentral

144.

Grisariu S, Avni B, Batchelor T T, Bent MJ van den, Bokstein F, Schiff, D, … Siegal T (2010). Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood, 115(24), 5005–5011. doi:https://doi.org/10.1182/BLOOD-2009-12-258210.

145.

Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology, 14(suppl 4), v45–v54. https://doi.org/10.1093/neuonc/nos203.CrossRef

146.

Ness, K. K., Hudson, M. M., Pui, C. H., Green, D. M., Krull, K. R., Huang, T. T., Robison, L. L., & Morris, E. B. (2012). Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer, 118(3), 828–838. https://doi.org/10.1002/cncr.26337.CrossRefPubMed

147.

Chu, S. H., Lee, Y. J., Lee, E. S., Geng, Y., Wang, X. S., & Cleeland, C. S. (2015). Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: A systematic review. Support Care Cancer, 23(2), 513–524. https://doi.org/10.1007/s00520-014-2408-8.CrossRefPubMed

148.

Hou, S., Huh, B., Kim, H. K., Kim, K. H., & Abdi, S. (2018). Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician, 21(6), 571–592.PubMed

Titel: Neurological complications of pediatric cancer
verfasst von: Caren Armstrong
Lisa R. Sun
Publikationsdatum: 13.01.2020
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2020
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09847-0

Springer Medizin

Neurological complications of pediatric cancer

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Signaling pathways in Rhabdomyosarcoma invasion and metastasis

Clinical research tools in pediatric oncology: challenges and opportunities

What recent primary studies tell us about ovarian teratomas in children: a scoping review

Neurocognitive impairment in Asian childhood cancer survivors: a systematic review

Pediatric medulloblastoma in the molecular era: what are the surgical implications?

Pediatric hemispheric high-grade glioma: targeting the future

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie